
    
      Multicenter, open-label, randomized (allocation ratio 1:1), cross-over with two treatment
      phases of 16 weeks each in two treatment groups:

        -  Study arm with insulin glargine + insulin lispro (phase 1) and insulin NPH + regular
           insulin (phase 2)

        -  Insulin NPH + regular insulin (phase 1) and insulin glargine + insulin lispro (phase 2)
    
  